HSDT - Helius Medical Technologies, Inc.
2.5700 0.00 (0.00%)
After hours: 5:55PM EDT
| Previous Close | 2.6900 |
| Open | 2.6800 |
| Bid | 2.5200 x 1000 |
| Ask | 3.0000 x 3200 |
| Day's Range | 2.5600 - 2.7100 |
| 52 Week Range | 1.7700 - 11.9100 |
| Volume | 181,610 |
| Avg. Volume | 200,239 |
| Market Cap | 66.476M |
| Beta (3Y Monthly) | -1.71 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.1800 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.12 |
- CNW Group•5 days ago
/C O R R E C T I O N from Source -- Helius Medical Technologies, Inc./
In the news release, Helius Medical Technologies to talk science behind PoNSTM device at Rehab Week, issued 20-Jun-2019 by Helius Medical Technologies, Inc. over CNW, the "TM" symbol in PoNS was not superscripted, as issued inadvertently. TORONTO , June 20, 2019 /CNW/ - Helius Medical Technologies, Inc. (HSDT) (HSM.TO) ("Helius" or the "Company"), a neurotech company focused on neurological wellness, will be hosting a scientific lecture at the fourth-annual Rehab Week, a global cross-disciplinary conference among engineers, researchers and clinicians in the field of rehabilitation technology. The lecture, which will be offered twice during Rehab week, will provide an overview of a new, non-invasive treatment option in Canada for those suffering from chronic balance deficit as a result of mild-to-moderate traumatic brain injury.
- GlobeNewswire•7 days ago
Helius Medical Technologies, Inc. Provides a Business Update on FDA Strategy
Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today is providing an update on its strategy to resubmit an application for De Novo clearance of its Portable Neuromodulation Stimulator (PoNS™) device with the U.S. Food and Drug Administration (the “FDA”). Since the Company received the letter from the FDA in April denying its submission for De Novo clearance of the PoNS device, it has been developing a strategy to resubmit an application to the FDA. As part of that strategy, members of the Company’s management participated in an informational discussion with the FDA on June 3rd regarding the issues the FDA raised in its April response letter.
- GlobeNewswire•14 days ago
Helius Medical Technologies, Inc. Announces Scientific Publication Confirming Tongue Stimulation with PoNS™ Alters Brain Activity
Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today reported that a scientific paper entitled Human Translingual Neurostimulation Alters Resting Brain Activity in High-density EEG was published in the latest edition of the peer reviewed Journal of NeuroEngineering and Rehabilitation. This high-density array electroencephalograph (“EEG”) study of the Portable Neuromodulation Stimulator (PoNS™) demonstrates brain activity changes following exposure to both the high (“HFP”) and low frequency pulse (“LFP”) versions of the PoNS device used in the Company’s traumatic brain injury clinical trials.
- GlobeNewswire•18 days ago
Helius Medical Technologies to Present at the JMP Securities Life Sciences Conference
Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that management will participate in the JMP Securities Life Sciences Conference at the St. Regis New York Hotel in New York, New York. A live audio webcast of the conference presentation will be provided under the ‘Events’ section of the Helius Medical Technologies investor relations website at https://heliusmedical.com/index.php/investor-relations/events/upcoming-events. The Portable Neuromodulation Stimulator (PoNS) is a licensed class II, noninvasive, medical device in Canada intended for use as an acute treatment of chronic balance deficit due to mild-to-moderate traumatic brain injury and is to be used in conjunction with physical therapy.
- GlobeNewswire•20 days ago
Glancy Prongay & Murray LLP Announces Investigation on Behalf of Helius Medical Technologies, Inc. Investors (HSDT)
LOS ANGELES, June 05, 2019 -- Glancy Prongay & Murray LLP (“GPM”) announces an investigation on behalf of Helius Medical Technologies, Inc. (“Helius” or the “Company”).
- GlobeNewswire•20 days ago
Helius Medical Technologies, Inc. Announces Addition of Three New PoNS™ Authorized Clinics in Canada
Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today reported that three new clinics have been authorized to provide PoNS Treatment™ in Canada, giving Canadians broader regional access to the Company’s innovative treatment. The new clinics join the current roster of existing clinics authorized to provide the PoNS Treatment, including Neurotherapy Montreal and Surrey Neuroplasticity Clinic. Since opening the first authorized clinic, Neurotherapy Montreal in Quebec, in December 2018, and the second authorized clinic, Surrey Neuroplasticity Clinic in British Columbia, in February 2019, the Company has made it a priority to make the PoNS accessible to patients from coast-to-coast.
- Business Wire•last month
Glancy Prongay & Murray LLP Continues Investigation on Behalf of Helius Medical Technologies, Inc. Investors (HSDT)
Glancy Prongay & Murray LLP (“GPM”) announces the continuation of its investigation on behalf of Helius Medical Technologies, Inc. (“Helius” or the “Company”) (NASDAQ: HSDT) investors concerning the Company and its officers’ possible violations of federal securities laws. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to shareholders@glancylaw.com, or visit our website at www.glancylaw.com. On April 10, 2019, Helius announced that the U.S. Food and Drug Administration (“FDA”) declined the Company’s request for De Novo classification and 510(k) clearance of the Company’s Portable Neuromodulation Stimulator (PoNS™) device.
- GlobeNewswire•2 months ago
Helius Medical Technologies, Inc. Reports First Quarter 2019 Financial Results and Provides Business Update; Reaffirms Full Year 2019 Outlook
NEWTOWN, Pa., May 09, 2019 -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today.
- GlobeNewswire•2 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Helius Medical Technologies, Inc. - HSDT
Pomerantz LLP is investigating claims on behalf of investors of Helius Medical Technologies, Inc. (“Helius” or the “Company”) (NASDAQ: HSDT). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. On April 10, 2019, Helius disclosed that the U.S. Food and Drug Administration (“FDA”) had declined the Company’s request for De Novo classification and clearance of its Portable Neuromodulation Stimulator device. The FDA stated that it lacked sufficient data to determine the relative contributions of the device and physical therapy in clinical studies. On this news, Helius’s stock price fell $44.11 per share, or 66.18%, to close at $2.10 per share on April 10, 2019, damaging investors.
- ACCESSWIRE•2 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Helius Medical Technologies, Inc. - HSDT
NEW YORK, NY / ACCESSWIRE / April 16, 2019 / Pomerantz LLP is investigating claims on behalf of investors of Helius Medical Technologies, Inc. ("Helius" or the "Company") (NASDAQ: HSDT). ...
- GlobeNewswire•2 months ago
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Helius Medical Technologies, Inc. - HSDT
Pomerantz LLP is investigating claims on behalf of investors of Helius Medical Technologies, Inc. (“Helius” or the “Company”) (NASDAQ: HSDT). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. On April 10, 2019, Helius disclosed that the U.S. Food and Drug Administration (“FDA”) had declined the Company’s request for De Novo classification and clearance of its Portable Neuromodulation Stimulator device. The FDA stated that it lacked sufficient data to determine the relative contributions of the device and physical therapy in clinical studies. On this news, Helius’s stock price fell $44.11 per share, or 66.18%, to close at $2.10 per share on April 10, 2019, damaging investors.
- Business Wire•2 months ago
INVESTOR ALERT: Kirby McInerney LLP Announces an Investigation of Shareholder Claims Against Helius Medical Technologies, Inc.
The law firm of Kirby McInerney LLP is investigating potential claims against Helius Medical Technologies, Inc. . This investigation concerns whether Helius has violated federal securities laws and/or engaged in other unlawful business practices.
- Business Wire•2 months ago
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Helius Medical Technologies, Inc. Investors
Law Offices of Howard G. Smith announces an investigation on behalf of Helius Medical Technologies, Inc. investors concerning the Company and its officers’ possible violations of federal securities laws.
- Benzinga•2 months ago
The Daily Biotech Pulse: NASH Cheer For Intercept, Gilead Layoffs, BioDelivery Licenses Constipation Drug
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on April 10) Fulgent Genetics Inc (NASDAQ: FLGT ) Intuitive Surgical, ...
- ACCESSWIRE•2 months ago
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Helius Medical Technologies, Inc. (HSDT)
NEW YORK, NY / ACCESSWIRE / April 10, 2019 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Helius Medical Technologies, Inc. ("Helius" or the ...
- GlobeNewswire•2 months ago
Helius Medical Technologies, Inc. Investigated by Block & Leviton LLP For Violations of Federal Securities Laws
BOSTON, April 10, 2019 -- Block & Leviton LLP (www.blockesq.com), a securities litigation firm representing investors nationwide, is investigating whether Helius Medical.
- MarketWatch•2 months ago
UPDATE: Helius Medical stock tanks after FDA declines request for approval of device used in brain injuries
Helius Medical Technologies Inc. shares slid 56% premarket Wednesday, after the company said the U.S. Food and Drug Administration has declined its request for De Novo classification and clearance of its Portable Neuromodulation Stimulator device (PoNS). The agency said it did not have enough data to determine the relative contributions of the device and physical therapy in clinical studies, but said the company could generate additional data and resubmit its application. The PoNS is a medical device used in Canada for the treatment of chronic balance deficit due to mild-to-moderate traumatic brain injury when used with physical therapy. It remains an investigational device in the U.S. and European Union, where it is still under review. "We are understandably disappointed by the Agency's decision to decline our request for De Novo classification and 510(k) clearance, but Helius remains committed to generating the data to pursue a De Novo classification and 510(k) clearance of our PoNS device in the future for the treatment of patients with chronic balance deficit due to mmTBI, in order to bring our innovative therapy to more than 1.5 million Americans suffering from this condition," Helius Chief Executive Philippe Deschamps said in a statement. Helius stock has fallen 24% in the last 12 months, while the S&P 500 has gained 8.3%.
- GlobeNewswire•2 months ago
Helius Medical Technologies, Inc. Provides Update on FDA’s Review of its Request for De Novo Classification and 510(k) Clearance of the PoNS™ Device
Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that the U.S. Food and Drug Administration (the “FDA” or the “Agency”) has completed its review of the Company’s request for De Novo classification and 510(k) clearance of the Portable Neuromodulation Stimulator (PoNS™) device and has declined the Company’s request. In reaching its conclusion, the Agency noted that it did not have sufficient information to discern the relative independent contributions of the PoNS Device and physical therapy on the improvements from baseline in the effectiveness endpoints observed in the Company’s clinical studies.
- GlobeNewswire•3 months ago
Helius Medical Technologies to Release First Quarter of Fiscal Year 2019 Financial Results on May 9, 2019
Helius Medical Technologies, Inc. (HSDT) (HSM.TO) (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced that first quarter of fiscal year 2019 financial results will be released after the market closes on Thursday, May 9, 2019. A live webcast of the call will also be provided on the Events section of the Company's investor relations website at https://heliusmedical.com/index.php/investor-relations/events/upcoming-events. The webcast will be archived on the Events section of the Company’s investor relations website.
- ACCESSWIRE•3 months ago
Uptick Newswire Hosts Helius Medical Technologies, Inc. on The Stock Day Podcast to Discuss Milestones in Their PoNS Technology
PHOENIX, AZ / ACCESSWIRE / March 20, 2019 / Uptick Newswire Stock Day Podcast welcomed Helius Medical Technologies, Inc. (HSDT) ("the Company"), a neurotech company focused on neurological wellness. President and CEO, Phil Deschamps, joined Stock Day host Everett Jolly. Jolly began the interview by asking Deschamps to share some background information about the Company.
- Simply Wall St.•3 months ago
The Helius Medical Technologies (NASDAQ:HSDT) Share Price Has Gained 90% And Shareholders Are Hoping For More
While Helius Medical Technologies, Inc. (NASDAQ:HSDT) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 21% in the last quarter. ButRead More...
